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Introduction
The cholera disease is a major source of suffering around the
world. This diarrheal disease is caused by the Vibrio cholerae
bacteria, but it is the cholera toxin (CT) it produces that is the
actual pathogenic species. The toxin attaches itself to the in-
testinal cell wall where it is subsequently internalized and the
A-subunit of this AB5 toxin
[1] subsequently initiates the disease
by raising the cellular cyclic adenosine monophosphate (cAMP)
concentration followed by fluid efflux into the intestines.[2] The
initial attachment of the toxin to the intestinal cell surface is
caused by the five B-subunits (CTB5) that surround the A-subu-
nit. While a single B binding site already binds with nanomolar
affinities to a GM1-oligosaccharide (GM1os), simultaneous
binding of more than one B-subunit of the toxin can greatly
enhance its affinity (Figure 1). Blocking the initial attachment
of the toxin to the cell surface has the potential to block the
disease. Considering the fact that the toxin itself takes advant-
age of multivalency[3, 4] in its binding to the cell surface, it was
clear that, in order to interfere effectively, a multivalent ligand
system would have to be designed.
Several evaluated multivalent systems have been designed
based on dendrimers,[5, 6] polymers[7, 8] peptides,[9] and also pen-
tavalent scaffolds[10–12] and have clearly shown the promise of
the multivalency approach.[13–16] In one such approach we at-
tached the GM1os to dendritic scaffolds of varying valencies.
Especially effective were the tetra- and octavalent systems,
which were able to inhibit CTB5 at subnanomolar concentra-
tions and with potency enhancements orders of magnitude
larger than the corresponding monovalent ligand.[17]
Subsequent studies with the close relative of the cholera
toxin, the heat labile enterotoxin of E. coli (LT), showed that
the multivalent ligands, when mixed with the toxin, would
lead to aggregates involving many toxin molecules.[18] This was
shown by analytical ultracentrifuge experiments as well as by
atomic force microscopy. The observed aggregation was attrib-
uted to the mismatch in valency between the multivalent
ligand (four or eight) and the multisubunit toxin (five). In fact,
it was considered a possibility that the enormous potency en-
hancements observed in the inhibition assay with the cholera
toxin could be due to the mismatch and the subsequent ag-
gregation that the multivalent ligands initiated. On the other
hand, there were reports in the literature, which described
symmetrical pentavalent CT or LT ligands that were shown to
be potent toxin inhibitors that clearly formed a 1:1 complex
with the toxin, as judged by dynamic light scattering (DLS) ex-
The five B-subunits (CTB5) of the Vibrio cholerae (cholera) toxin
can bind to the intestinal cell surface so the entire AB5 toxin
can enter the cell. Simultaneous binding can occur on more
than one of the monosialotetrahexosylganglioside (GM1) units
present on the cell surface. Such simultaneous binding arising
from the toxin’s multivalency is believed to enhance its affinity.
Thus, blocking the initial attachment of the toxin to the cell
surface using inhibitors with GM1 subunits has the potential to
stop the disease. Previously we showed that tetravalent GM1
molecules were sub-nanomolar inhibitors of CTB5. In this study,
we synthesized a pentavalent version and compared the bind-
ing and potency of penta- and tetravalent cholera toxin inhibi-
tors, based on the same scaffold, for the first time. The penta-
valent geometry did not yield major benefits over the tetrava-
lent species, but it was still a strong inhibitor, and no major
steric clashes occurred when binding the toxin. Thus, systems
which can adopt more geometries, such as those described
here, can be equally potent, and this may possibly be due to
their ability to form higher-order structures or simply due to
more statistical options for binding.
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periments.[10] Based on the 1:1 design, several pentavalent CT
inhibitors were reported, and it was suggested that this design
was beneficial to the inhibition.[11,12] This also included a modi-
fied version of the cholera toxin that can no longer bind GM1
and was outfitted with 5GM1os ligands.[19] The related Shiga-
like toxin has also seen a potent inhibitor with five arms for
each subunit.[20] Potent inhibition was seen, although the bind-
ing mode, involving two toxins, was not as expected, as the
two ligands per arm engaged two separate toxins rather than
two binding sites per toxin subunit. However, so far, no experi-
ments were undertaken that compared a matching pentava-
lent CT inhibitor with inhibitors of nonmatching valencies
based on closely related scaffolds. Therefore, it remains very
much unclear which of the two approaches—1:1 design or
mismatch-aggregation—is the best. We now address this ques-
tion and report on the synthesis and evaluation in the same
assay of tetra- and pentavalent GM1-based ligand systems for
CT inhibition.
Results and Discussion
Synthesis
The synthesis started with the preparation of the scaffold for
the tetravalent inhibitor 5, which was subsequently used for
the preparation of the scaffold for the pentavalent inhibitor 8
(Scheme 1). The overall design of the tetravalent inhibitor was
kept close to the previous version (inhibitor 11)[17] although
there were differences in the spacer arms due to the availabili-
ty and use of a different GM1os building block, that is, 6 in
this case. The length of the spacer arm was almost the same
as before, with the present one just measuring two atoms
longer. Furthermore, the previous partly hydrophobic and
partly hydrophilic spacer arm was now replaced by one con-
sisting almost entirely of hydrophilic ethylene glycol units.
The synthesis started with the elongation of the four arms
of 1 as previously described.[5] The spacer 2[21] was coupled to
the dendritic scaffold 1 by the action of benzotriazol-1-yloxy-
tris(dimethylamino)-phosphonium hexafluorophosphate (BOP)
and N,N-diisopropylethylamine (DIPEA), which resulted in 3 in
50% yield. After that, trifluoroacetic acid (TFA) was used to
remove the Boc protecting group from the amino groups of 3,
and a coupling reaction between 3 and 4[22] using 1-[bis(dime-
thylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate (HATU) and DIPEA afforded the tetramer-
ic full length scaffold 5 in 60% yield over two steps. Micro-
wave-assisted copper(I)-catalyzed azide–alkyne cycloaddition
(CuAAC) was subsequently used to conjugate the GM1os deriv-
ative 6 to the scaffold 5, which efficiently yielded the tetrava-
lent GM1 derivative 7. The latter was purified by preparative
high-performance liquid chromatography (HPLC).
The tetravalent scaffold 5 formed the starting point for the
synthesis of the pentavalent version (Scheme 1, steps e—g). To
this end, the methyl ester of 5 was saponified quantitatively by
base. The resulting carboxylic acid was coupled to the com-
mercially available spacer 9 using BOP and DIPEA, which suc-
cessfully gave 8 as the pentavalent scaffold in 51% yield over
two steps. Subsequently, a microwave-assisted CuAAC conju-
gation reaction was employed on 8 and 6 leading to the for-
mation of the pentavalent GM1 derivative 10, which was puri-
fied by preparative HPLC.
Inhibition
The compounds were evaluated as CTB5 inhibitors using an
assay similar to an enzyme-linked immunosorbent assay
(ELISA), as previously described.[17] A 96-well ELISA plate was
coated by the natural bovine brain GM1 ganglioside. The re-
maining binding sites were blocked with bovine serum albu-
min (BSA). Horseradish peroxidase (HRP)-conjugated CTB5 was
incubated with varying concentrations of the tested inhibitors
for 2 h at room temperature. After that, the remaining activity
of CTB5 was measured upon addition of the solutions to the
Figure 1. a) X-ray structure of the cholera toxin B-subunit (CTB) bound to
GM1os (PDB ID: 3CHB); b, c) General architecture of the tetravalent (b) and
pentavalent (c) ligands described here.
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Scheme 1. Synthesis of the pentavalent inhibitor. The boxes show the core structure (left) and the oligosaccharide (X, right). Reagents and conditions ; a) 2,
BOP, DIPEA, DMF, rt, o/n, 40%; b) TFA, CH2Cl2, rt, 3 h; c) 4, HATU, DIPEA, DMF, rt, o/n, 60%; d) 6, CuSO4·5H2O, Na ascorbate, DMF/H2O 1:1, microwave, 80 8C,
20 min, 30%; e) dioxane/MeOH/4 n NaOH 30:9:1, rt until hydrolyzed; f) 9, BOP, DIPEA, DMF, rt, o/n, 51%; g) 6, CuSO4·5H2O, Na ascorbate, DMF/H2O 1:1, micro-
wave, 80 8C, 20 min, 41%.
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wells and incubation for 30 min at room temperature to allow
for binding of the remaining toxin. After incubation and wash-
ing, the amount of bound toxin was quantified by using a chro-
mogenic substrate for HRP. The previously reported[17] tetrava-
lent GM1 compound 11 was used here as a reference in inhibi-
tory potency evaluation. In the present assay, 11 showed an
IC50 of 190 pm, a value close to the previously reported one
(230 pm) (Table 1). The new tetravalent GM1 compound 7 ex-
hibited a very similar inhibitory potency, with an IC50 of
160 pm. This result shows that a slightly different spacer length
and considerably different spacer polarity did not lead to sig-
nificantly different inhibitory properties. The pentavalent GM1
derivative 10 exhibited an IC50 of 260 pm, which is in the same
range as the values found for both of the tetravalent ligands.
This indicates that in our assay, the potency of the ligand of
matching valency does not essentially differ from the poten-
cies of its nonmatching analogues.
Sedimentation velocity analytical ultracentrifugation
(SV-AUC)
In order to learn whether the pentavalent geometry of 10
leads to a different, possibly less aggregative, binding mode,
SV-AUC[23,24] experiments were undertaken. First a sample with
just CTB5 was measured. It contained a single species with
a sedimentation coefficient of 4.4 S corresponding to a mass of
58 kDa for the protein pentamer. Sisu et al.[18] previously used
SV-AUC to test the tetrameric GM1os dendrimer 11 with LTB5,
and it was found to strongly aggregate the protein while no
discrete oligomers were observed. In the present experiments,
tetravalent inhibitor 7, which is structurally similar to 11, was
added to CTB5 at a pentamer concentration of 50 mm. With the
addition of 0.2–1.0 equivalents, a dramatic reduction in the
overall signal was observed, as had previously been shown for
11 and LTB5, indicating rapid sedimentation of aggregating
large particles (Figure 2, see also Supporting Information).
However, with inhibitor 7, the emergence of a peak at 7.2
0.2 S was seen with a predicted mass of approximately
110 kDa, which corresponds to a dimer of CTB pentamers. With
increasing amounts of inhibitor up to 10 equivalents, the
amount of the dimer species increased, and the emergence of
some stable CTB pentamers was also observed. Excess and un-
bound inhibitor was observed as a peak at 0.90.1 S corre-
sponding to a mass of 8 kDa.
Pentavalent inhibitor 10 matched the number of ligand
groups to the number of binding sites of CTB5 and so it was
expected that this inhibitor should form stable 1:1 complexes.
However, the AUC results were very similar to those observed
for tetravalent ligand 7. A reduction in signal indicated large
scale aggregation, and some dimerization of CTB pentamers
was observed. Again, at higher equivalents of inhibitor, some
CTB pentamers were seen but with no significant difference to
the tetravalent inhibitor.
Conclusions
For the first time, penta- and tetravalent cholera toxin inhibi-
tors based on the same scaffold were compared. The struc-
tures contained arms of sufficient length to simultaneously
bridge all binding sites (see Supporting Information). Cleary,
the pentavalent geometry of 10 did not yield major benefits
over the tetravalent 7; in fact, it was a little worse. However, it
was still a strong inhibitor, so major steric clashes did not
occur in the binding of 10 to the toxin. Nevertheless one can
argue that the potency per arm is significantly reduced by
a factor of about two. Both 7 and 10 behaved very similarly in
sedimentation velocity analytical ultracentrifugation (SV-AUC).
As noted before for 11, aggregation occurs upon toxin bind-
ing, resulting in higher order structures, while only minor
amounts of bound pentamer (or its dimer) could be detected.
The arms of the systems described here are designed in agree-
ment with the concept that their ‘effective length’[10] should
match the distance they should cover. The lengths of their ex-
tended conformations are therefore far longer. While the fifth
arm is slightly shorter than the other four, it should be kept in
mind that it is easily capable of bridging the fifth site, and that
is attached to a different site of the scaffold.
It is of interest to compare our results to related pentavalent
systems in the literature. Even though inhibition assay results
cannot be directly compared, it is a fact that the same assay is
used in these studies. One pentavalent GM1 system, based on
a corranulene scaffold, exhibited an IC50 of 5 nm, presumably
Table 1. Potency of the inhibitors[a]
Compound Valency IC50 [nm]
11 4 0.19 (0.02)
7 4 0.16 (0.04)
10 5 0.26 (0.02)
[a] Determined in an ELISA-like assay with CTB5–HRP (40 ng/mL) and
wells coated with GM1.
Figure 2. Sedimentation velocity analytical ultracentrifugation profiles of
tetravalent 7 (a) and pentavalent 10 (b), recorded with increasing amounts
of multivalent ligand (legend for both graphs).
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not living up to its full potential due to self-association of the
scaffold.[12] A related calix[5]arene-based system showed higher
potency with an IC50 of 450 pm.
[11] Neither of these systems
showed a compelling argument in favor of a pentavalent
system, consistent with our results. CTB5, whose binding sites
were disabled, was recently used as a scaffold for the display
of five GM1 units. This construct showed an IC50 of 104 pm and
was shown to form a 1:1 complex with the toxin. While im-
pressive, it is not very different from the 160 pm observed
here, nor the 50 pM value for our previously reported octava-
lent GM1 structure. [17]
It seems that a preorganized system can indeed bind in
a 1:1 fashion with CTB5 ;
[19] however, systems which can adopt
more geometries, such as those described here, can be equally
potent, and this may possibly be due to their ability to form
higher-order structures or simply due to more statistical op-
tions for binding. Bundle and Kitov provided theoretical sup-
port for the latter to explain the enhancements in the inhibi-
tion of AB5 toxins.
[25] Their model emphasized the importance
of a statistical term that describes in how many ways a multiva-
lent ligand can bind to multiple binding sites—this was called
avidity entropy. This was used to explain why an octavalent
system was a better Shiga-like toxin inhibitor than the
matched pentavalent one.
Experimental Section
General remarks : Unless stated otherwise, chemicals were ob-
tained from commercial sources and used without further purifica-
tion. Solvents were purchased from Biosolve (Valkenswaard, the
Netherlands). Acid spacers 2[13] and 4[22] were synthesized following
literature procedures. Compound 6 was purchased from Elicityl
(Crolles, France). Microwave reactions were carried out in a dedicat-
ed microwave oven: the Biotage Initiator (Uppsala, Sweden). The
microwave power was limited by temperature control once the de-
sired temperature was reached. A sealed vessel of 2–5 mL was
used. Analytical HPLC runs were performed on a Shimadzu auto-
mated HPLC system (Kyoto, Japan) with a reversed-phase column
(Reprospher 100, C8, 5 mm, 250X4.6 mm, Dr. Maisch GmbH, Am-
merbuch-Entringen, Germany), equipped with an evaporative light-
scattering detector, PLELS 1000 (Polymer Laboratories, now Varian,
Inc. , Palo Alto, USA) and a Shimadzu SPD-10A VP UV/Vis detector
operating at 220 and 254 nm. Preparative HPLC runs were per-
formed on an Applied Biosystems workstation (Waltham, USA). Elu-
tion was performed using a gradient of 5% CH3CN and 0.1% TFA
in H2O to 5% H2O and 0.1% TFA in CH3CN.
1H NMR (400 MHz) and
13C NMR (100 MHz) spectra were recorded on an Agilent 400-MR
spectrometer (Santa Clara, USA). Heteronuclear single quantum co-
herence (HSQC) spectroscopy and total correlated spectroscopy
(TOCSY) NMR (500 MHz) measurements were performed on
a VARIAN INOVA-500 (Palo Alto, USA). Electrospray ionization mass
spectrometry (ESI-MS) experiments were performed on a Shimadzu
LCMS QP-8000. High resolution quadrupole–time-of-flight mass
spectrometry (HRMS-QTOF) analysis was recorded using Bruker ESI-
Q-TOF II (Billerica, USA). The proton numbering scheme of all com-
pounds can be found in the Supporting Information and is used in
the assignments of the signals in the NMR spectra here.
CTB5 inhibition assay : A 96-well plate was coated with a solution
of GM1 (100 mL, 2 mgmL¢1) in phosphate buffered saline (PBS). Un-
attached ganglioside was removed by washing with PBS twice,
and the remaining binding sites of the surface were blocked with
BSA (1%), which was followed by washing with PBS three times.
Samples of toxin–peroxidase conjugate (final concentration of 40
ng/ml CTB-HRP, Sigma) and inhibitor (final concentration of 10¢6–
10¢12 m) in PBS with BSA (0.1%)/Tween-20 (0.05%) were incubated
at rt for 2 h and were then transferred to the GM1-coated plate.
After 30 min of incubation, the solution was removed and the
wells were washed three times with PBS with BSA (0.1%)/Tween-
20 (0.05%). To identify toxin binding to surface-bound GM1, the
wells were treated with a freshly prepared solution of o-phenylene-
diamine/H2O2 in citrate buffer (pH 4.5, 100 mL) for 15 min. After
being quenched with H2SO4 (2.5 m, 50 mL), the absorbance in each
well was measured at 490 nm. Inhibition data from three experi-
ments were averaged and fitted in GraphPad Prism 5.0 (La Jolla,
USA). (See Supporting Information for examples of the fitted data.)
Analytical ultracentrifugation experiments : Mixtures of CTB5 with
various amounts of inhibitors were prepared within 1 h before
analysis was carried out. Samples (0.4 mL) were centrifuged in
12 mm pathlength 2-sector Al-centerpiece cells with sapphire win-
dows in a An60Ti analytical rotor running in an Optima XL-I or
Optima XL-A analytical ultracentrifuge (Beckman Instruments, Inc. ,
Palo Alto, USA) at 60 krpm and at 25 8C. Changes in solute concen-
tration were detected by 300 absorbance scans measured at
280 nm over a period of 5–6 h. Analysis and fitting of the data was
performed using the software SedFit v.14.3.[26] A continuous c (s)
distribution model was fitted to the data, taking every 2nd scan.
The resolution was set at 200 over a sedimentation coefficient
range of 0.0–15.0 S. Parameters were set for the partial specific
volume as 0.73654 mLg¢1, the buffer density of 1.04910 gmL¢1,
and the buffer viscosity at 0.00141 Pas, as calculated using
SEDNTERP v.2.0 for 0.1m PBS. The frictional coefficient, the base-
line, and the raw data noise were floated in the fitting. The menis-
cus and bottom of the cell path were also floated after initial esti-
mations from the raw data.
Compound 3 : To a solution of tetraamine 1[5] (443 mg, 0.82 mmol)
and spacer 2[21] (1.7 g, 3.90 mmol) in dry dimethylformamide (DMF,
15 mL), BOP (2.56 g, 5.79 mmol) and DIPEA (1.48 g 11.48 mmol)
were added. The mixture was stirred at rt overnight and then con-
centrated in vacuo. The residue was purified by silica gel chroma-
tography to afford 3 (780 mg, 50%). 1H and 13C NMR were consis-
tent with ref. [5] MS (ESI) m/z [M+2H¢2ÕBoc]2+ calcd for
C105H174N14O40 :1086.58, found 1086.75.
Compound 5 : Compound 3 (780 mg, 0.33 mmol) was treated with
TFA in CH2Cl2 (1:1, 20 mL) for 3 h at rt, after which the volatiles
were removed under reduced pressure, and the residue was dried
under high vacuum. Meanwhile, compound 4 was prepared follow-
ing the literature procedure.[22] The obtained amine TFA salt of 3
and the spacer 4 (670 mg, 2.30 mmol) were dissolved in anhydrous
DMF (15 mL), then HATU (875 mg, 2.30 mmol) and DIPEA (892 mg,
6.90 mmol) were added. The mixture was stirred at rt overnight
and then concentrated in vacuo. The residue was purified by silica
gel chromatography to afford 5 (600 mg, 60%); 1H NMR (400 MHz,
CDCl3): d=7.70, 7.58, 7.40, 6.81 (14H, 4Õbr t, J=5 Hz, C(O)NH),
7.15 (2H, s, CH, aryl-2, aryl-6), 6.99 (4H, s, CH, 2Õaryl-2’, 2Õaryl-6’),
6.70 (1H, s, CH, aryl-4), 6.54 (2H, s, CH, 2Õaryl-4’), 4.17, 4.06 (12H,
2Õbr t, J=5 Hz, OCH2CH2NH), 4.02, 3.99 (2Õ8H, 2Õs, OCH2C(O)),
3.86 (3H, s, C(O)OCH3), 3.82–3.75 (4H, m, OCH2CH2NH), 3.72–3.43
(120H, m, OCH2, OCH2CH2NH), 3.40–3.32 (16H, m, OCH2CH2N3,
CH2NHC(O)), 3.32–3.24 (8H, m, CH2NHC(O)), 2.42 (8H, t, J=5 Hz,
C(O)CH2CH2O), 1.82–1.66 ppm (16H, m, OCH2CH2CH2NH);
13C NMR
(100 MHz, CDCl3): d=171.16, 169.52, 168.85, 167.51 (C(O)NH),
166.68 (C(O)OCH3), 159.84, 159.70 (C, aryl), 136.69 (C, aryl), 132.14
ChemistryOpen 2015, 4, 471 – 477 www.chemistryopen.org Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim475
(C, aryl), 108.31 (CH, aryl-2, aryl-6), 106.76 (CH, aryl-4), 106.41 (CH,
aryl-2’, aryl-6’), 104.70 (CH, aryl-4’), 71.02 (OCH2C(O)), 70.72–69.35
(OCH2), 67.35 (OCH2), 66.89, 66.62 (OCH2CH2NH), 52.40 (C(O)OCH3),
50.74 (OCH2CH2N3), 39.72, 38.46 (OCH2CH2NH), 37.22, 37.04
(CH2NHC(O)), 36.81 (C(O)CH2CH2O), 29.38, 29.14 ppm
(OCH2CH2CH2NH); MS (ESI) m/z [M+3H]
3+calcd for C134H226N26O54 :
1022.12, found 1022.40; HRMS (QTOF) m/z [M+3H]3+calcd for
C134H226N26O54 : 1022.5257, found 1022.5348.
Compound 7: A solution of tetravalent 5 (7 mg, 2.28 mmol), 6
(14.8 mg, 13.4 mmol), sodium ascorbate (8.1 mg, 41.1 mmol), and
CuSO4·5H2O (5.1 mg, 20.6 mmol) in DMF/H2O (1:1, 2 mL) was pre-
pared and heated under microwave irradiation at 80 8C for 20 min.
After cooling down to rt, the copper salts were removed by a resin
(Cuprisorb) and filtered off. The filtrate was then concentrated in
vacuo, and the residue was purified by preparative HPLC and ob-
tained by freeze-drying as an off-white powder (5 mg, 30%);
1H NMR (500 MHz, D2O): d=8.06, 7.96 (4H, 2Õs, CH, triazole), 7.15
(2H, s, CH, aryl-2, aryl-6), 6.83 (5H, s, CH, 2Õaryl-2’, 2Õaryl-6’, aryl-
4), 6.68 (2H, s, CH, 2Õaryl-4’), 5.64, 5.15 (4H, 2Õd, J1,2=8 Hz, J1,2=
8 Hz, HGlc-1), 4.79 (4H, HGalNAc-1), 4.66–4.51 (24H, m, NCH2Ctriazole,
CH2Ntriazole, HGal-1, HGal’-1), 4.27–4.07 (12H, m, OCH2CH2NH), 4.10,
4.04 (2Õ8H, 2Õs, OCH2C(O)), 3.86 (3H, s, C(O)OCH3), 3.77–3.65
(12H, m, OCH2CH2NH), 3.65–3.45 (112H, m, OCH2), 3.41 (4H, t, J2,3=
J2,4=9 Hz, HGal-2), 3.31–3.17 (16H, m, CH2NHC(O)), 2.69 (4H, dd,
J3a,3b=13.5 Hz, J3a,4=4 Hz, HNeuAc-3), 2.48 (8H, t, J=6 Hz,
C(O)CH2CH2O), 2.25 (12H, s, NC(O)CH3), 2.04, 2.02 (2Õ12H, 2Õs,
NHC(O)CH3), 1.96 (4H, t, J3b,3a= J3b,4=11.5 Hz, HNeuAc-3), 1.78–
1.67 ppm (16H, m, OCH2CH2CH2NH);
13C NMR (125 MHz, D2O): d=
175.54, 175.27, 174.64, 174.24, 171.71 (COOH, C(O)NH), 164.71
(C(O)OCH3), 160.05 (C, aryl), 145.38 (C, triazole), 132.49 (C, aryl),
125.67, 125.42 (CH, triazole), 109.43 (CH, aryl-2, aryl-6), 106.94 (CH,
aryl-2’, aryl-6’, aryl-4), 105.55 (CH, aryl-4’), 105.35 (CGal’-1), 103.21
(CGal-1), 103.05 (CGalNAc-1), 102.22 (CNeuAc-2), 87.49, 82.91 (CGlc-1),
80.79 (CGalNAc-3), 78.65 (CGlc-4), 77.41 (CGlc-5), 77.30 (CGal-3), 75.50
(CGal’-5), 75.11 (CGal-4), 75.07 (CGalNAc-5), 75.06 (CGal-5), 73.62 (CNeuAc-6),
73.07 (CGal’-3), 72.54 (CNeuAc-8), 71.28 (CGal’-2), 70.60 (CGal’-4), 70.54
(OCH2C(O)), 70.50 (CNeuAc-7, CGal-2), 70.49 (OCH2C(O)), 70.12 (OCH2),
70.02 (OCH2), 69.99 (OCH2), 69.25 (CGalNac-4), 69.02 (CNeuAc-4), 68.96
(OCH2), 68.49 (CGlc-3), 67.49 (OCH2CH2NH), 67.38 (CGlc-2), 67.25
(OCH2CH2NH), 63.48 (CNeuAc-9), 61.55 (CGalNAc-6, CGal’-6), 61.05 (CGal-6),
60.66 (CGlc-6), 53.39 (C(O)OCH3), 52.15 (CNeuAc-5), 51.86 (CGalNAc-2),
50.71 (CH2Ntriazole), 40.36, 39.05 (OCH2CH2NH), 37.73 (CNeuAc-3), 36.93
(CH2NHC(O)), 36.75 (NCH2Ctriazole), 36.66 (C(O)CH2CH2O), 28.85
(OCH2CH2CH2NH), 23.10 (CGalNAc-NHC(O)CH3), 22.61 (CNeuAc-
NHC(O)CH3), 21.76 ppm (CGlc-1-NC(O)CH3) ; HRMS (QTOF) m/z
[M¢3H]3¢ calcd for C302H486D8N38O170 : 2460.7688, found 2460.4179.
Compound 8 : The obtained tetramer 5 (305 mg, 0.10 mmol) was
treated with Tesser’s base[22] (dioxane/MeOH/4 n NaOH 30:9:1,
5 mL). The mixture was stirred at rt until the total disappearance of
the starting material. After that, the reaction was quenched by
adding 1 n KHSO4, and the mixture was concentrated in vacuo.
The residue was redissolved in CH2Cl2 (20 mL) and washed with
1 n KHSO4 (10 mL), H2O (10 mL), and brine (10 mL), dried on
Na2SO4, and concentrated in vacuo. The resulting acid was used for
the next step without further purification. To a solution of this acid
and amine spacer 9 (O-(2-Aminoethyl)-O’-(2-azidoethyl)heptaethy-
lene glycol, 70 mg, 0.16 mmol, Sigma–Aldrich) in dried DMF
(10 mL), BOP (60 mg, 0.13 mmol) and DIPEA (40 mg, 0.31 mmol)
were added. The mixture was stirred at rt overnight. Afterwards,
the reaction was stopped and concentrated. The residue was sus-
pend into CH2Cl2 (30 mL) and washed with 1 n KHSO4 (15 mL), 1 n
NaHCO3 (15 mL), H2O (15 mL), and brine (15 mL). The organic layer
was collected, dried on Na2SO4, and filtered. After concentration,
the resulting material was purified by silica gel chromatography to
afford 8 as a colorless oil (175 mg, 0.05 mmol, 51% over two
steps); 1H NMR (400 MHz, CDCl3): d=7.76, 7.67, 7.58, 7.47, 6.87
(15H, 5Õbr t, J=5 Hz, C(O)NH), 7.02 (2H, s, CH, aryl-2, aryl-6), 6.96
(4H, s, CH, 2Õaryl-2’, 2Õaryl-6’), 6.63 (1H, s, CH, aryl-4), 6.52 (2H, s,
CH, 2Õaryl-4’), 4.17, 4.05 (12H, 2Õb t, J=5 Hz, OCH2CH2NH), 4.02,
3.98 (2Õ8H, 2Õs, OCH2C(O)), 3.80–3.72 (4H, m, OCH2CH2NH), 3.71–
3.44 (152H, m, OCH2, OCH2CH2NH), 3.40–3.31 (20H, m, OCH2CH2N3,
CH2NHC(O)), 3.31–3.23 (8H, m, CH2NHC(O)), 2.42 (8H, t, J=5 Hz,
C(O)CH2CH2O), 1.80–1.68 ppm (16H, m, OCH2CH2CH2NH);
13C NMR
(100 MHz, CDCl3): d=171.69, 169.56, 168.91, 167.56, 167.29
(C(O)NH), 159.97, 159.70 (C, aryl), 136.82 (C, aryl), 136.69 (C, aryl),
106.48 (CH, aryl-2, aryl-6), 106.35 (CH, aryl-2’, aryl-6’), 104.81 (CH,
aryl-4), 104.72 (CH, aryl-4’), 71.02 (OCH2C(O)), 70.73–69.36 (OCH2),
67.38 (OCH2), 66.75, 66.62 (OCH2CH2NH), 50.75 (OCH2CH2N3), 40.01,
39.75, 38.49 (OCH2CH2NH), 37.22 (CH2NHC(O)), 36.93
(C(O)CH2CH2O), 29.39, 29.18 ppm (OCH2CH2CH2NH); MS (ESI) m/z
[M+3H]3+calcd for C151H260N30O61: 1157.61, found 1157.65,
[M+2H]2+ calcd for 1736.91, found 1736.65; HRMS (QTOF) m/z
[M+3H]3+calcd for C151H260N30O61: 1157.6055, found 1157.9647.
Compound 10 : A solution of pentavalent scaffold 8 (8.4 mg,
2.42 mmol), 6 (16 mg, 14.55 mmol), sodium ascorbate (6.92 mg,
35 mmol), and CuSO4·5H2O (4.35 mg, 17.4 mmol) in DMF/H2O (1:1,
2 mL) was prepared and heated under microwave irradiation at
80 8C for 20 min. After cooling down to rt, the copper salts were re-
moved by a resin (Cuprisorb) and filtered off. The filtrate was then
concentrated in vacuo, and the residue was purified by preparative
HPLC and obtained by freeze-drying as an off-white powder
(8.7 mg, 41%); 1H NMR (500 MHz, D2O): d=8.07, 7.96 (5H, 2Õs, CH,
triazole), 7.02 (2H, s, CH, aryl-2, aryl-6), 6.85, 6.80 (5H, 2Õs, CH, 2Õ
aryl-2’, 2Õaryl-6’, aryl-4), 6.70 (2H, s, CH, 2Õaryl-4’), 5.64, 5.15 (5H,
2Õd, J1,2=8.5 Hz, J1,2=8.5 Hz, HGlc-1), 4.78 (5H, HGalNAc-1), 4.67–4.52
(30H, m, NCH2Ctriazole, CH2Ntriazole, HGal-1, HGal’-1), 4.27–4.09 (12H, m,
OCH2CH2NH), 4.11, 4.05 (2Õ8H, 2Õs, OCH2C(O)), 3.76–3.65 (12H, m,
OCH2CH2NH), 3.68–3.45 (146H, m, OCH2, CH2NHC(O)), 3.40 (5H, t,
J2,3= J3,4=9 Hz, HGal-2), 3.29–3.19 (16H, m, CH2NHC(O)), 2.69 (5H,
dd, J3a,3b=13 Hz, J3a,4=4 Hz, HNeuAc-3), 2.49 (8H, t, J=6 Hz,
C(O)CH2CH2O), 2.26 (15H, s, NC(O)CH3), 2.04, 2.02 (2Õ15H, 2Õs,
NHC(O)CH3), 1.96 (5H, t, J3b,3a= J3b,4=11 Hz, HNeuAc-3), 1.80–
1.69 ppm (16H, m, OCH2CH2CH2NH);
13C NMR (125 MHz, D2O): d=
175.54, 175.28, 174.29, 174.14, 172.33, 171.75 (COOH, C(O)NH),
160.07 (C, aryl), 145.47 (C, triazole), 136.36 (C, aryl), 125.41, 125.39
(CH, triazole), 107.40 (CH, aryl-2, aryl-6), 106.89 (CH, aryl-2’, aryl-6’),
106.01 (CH, aryl-4), 105.51 (CH, aryl-4’), 105.28 (CGal’-1), 103.16
(CGal-1), 103.01 (CGalNAc-1), 101.76 (CNeuAc-2), 87.38, 82.87 (CGlc-1),
80.77 (CGalNAc-3), 78.59 (CGlc-4), 77.38 (CGal-3), 77.32 (CGlc-5), 75.45
(CGal’-5), 75.03 (CGalNAc-5), 74.98 (CGal-4), 74.73 (CGal-5), 73.64 (CNeuAc-6),
73.04 (CGal’-3), 72.56 (CNeuAc-8), 71.16 (CGal’-2), 70.59 (CNeuAc-7, CGal-2),
70.44 (OCH2C(O)), 70.37 (OCH2C(O)), 70.16 (CGal’-4), 70.10 (OCH2),
70.09 (OCH2), 70.03 (OCH2), 69.14 (CGalNac-4), 68.97 (CNeuAc-4), 68.94
(OCH2), 68.43 (CGlc-3), 67.41 (OCH2CH2NH), 67.32 (CGlc-2), 67.26
(OCH2CH2NH), 63.41 (CNeuAc-9), 61.49 (CGalNAc-6, CGal’-6), 60.88 (CGal-6),
60.61 (CGlc-6), 52.10 (CNeuAc-5), 51.76 (CGalNAc-2), 50.60 (CH2Ntriazole),
40.19, 40.17, 39.01 (OCH2CH2NH), 37.61 (CNeuAc-3), 36.83
(CH2NHC(O)), 36.70 (NCH2Ctriazole), 36.59 (C(O)CH2CH2O), 28.78
(OCH2CH2CH2NH), 23.08 (CGalNAc-NHC(O)CH3), 22.58 (CNeuAc-
NHC(O)CH3), 21.68 ppm (CGlc-1-NC(O)CH3) ; HRMS (QTOF) m/z [M+
5H+NH4]
6+calcd for C361H591D4N45O206 : 1481.1261, found
1481.4361.
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